NewAmsterdam Pharma Company N.V. Gains Losses On Exchange Differences On Translation Before Tax
NewAmsterdam Pharma Company N.V. (NAMS) reported Gains Losses On Exchange Differences On Translation Before Tax of EUR 2.77 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-07.
Financial Statements › Income Statement › Other Income
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax · last filed 2024-10-28
| Period end | Gains Losses On Exchange Differences On Translation Before Tax 6 month | Gains Losses On Exchange Differences On Translation Before Tax 12 month | Gains Losses On Exchange Differences On Translation Before Tax 12 month as first filed |
|---|---|---|---|
| 2023-06-30 | 2.77M EUR 6-K · filed 2023-08-07 | ||
| 2022-12-31 | -9.26M EUR 20-F/A · filed 2024-10-28 | ||
| 2022-06-30 | 1.07M EUR 6-K · filed 2023-08-07 | ||
| 2021-12-31 | 1.44M EUR 20-F/A · filed 2024-10-28 | ||
| 2020-12-31 | 24.00K EUR 20-F/A · filed 2024-10-28 | -24.00K EUR 20-F · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |